{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:27:12Z","timestamp":1784690832377,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.lungcan.2019.09.015","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:29:09Z","timestamp":1568806149000},"page":"71-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies"],"prefix":"10.1016","volume":"137","author":[{"given":"Jessica A.","family":"Hellyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Gubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Cunanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhmani K.","family":"Padda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Spittler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"San Pedro-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha J.","family":"Ramchandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-980X","authenticated-orcid":false,"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sr","given":"Patrick J.","family":"Loehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2019.09.015_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"15","key":"10.1016\/j.lungcan.2019.09.015_bib0010","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.09.015_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.09.015_bib0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1005862730941","article-title":"Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin","volume":"15","author":"Suzuki","year":"1997","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.lungcan.2019.09.015_bib0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1124\/jpet.111.190256","article-title":"Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin","volume":"341","author":"Salvatorelli","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2019.09.015_bib0030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2019.09.015_bib0035","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/jjco\/hyu136","article-title":"Successful salvage chemotherapy with amrubicin for invasive thymoma associated with myasthenia gravis","volume":"44","author":"Fukushima","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.09.015_bib0040","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12032-009-9223-y","article-title":"Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases","volume":"27","author":"Koizumi","year":"2010","journal-title":"Med. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2019.09.015_bib0045","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jjco\/hyt106","article-title":"Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma","volume":"43","author":"Hirai","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2019.09.015_bib0050","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2019.09.015_bib0055","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma","volume":"13","author":"Gbolahan","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2019.09.015_bib0060","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2019.09.015_bib0065","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.09.015_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2019.09.015_bib0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.09.015_bib0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.09.015_bib0085","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","author":"Cho","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.09.015_bib0090","doi-asserted-by":"crossref","DOI":"10.21037\/med.2018.08.05","article-title":"Pembrolizumab in patients with thymic carcinoma: a cautionary tale","author":"Hellyer","year":"2018","journal-title":"Mediastinum"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219306592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219306592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:29:54Z","timestamp":1759235394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219306592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":18,"alternative-id":["S0169500219306592"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}